Veloxis Pharmaceuticals, Inc., Appoints Ulf Meier-Kriesche, MD, as Chief Scientific Officer
September 13, 2017 17:27 ET
|
Veloxis Pharmaceuticals A/S
Company Release no. 19/2017
To: NASDAQ Copenhagen A/S ...
Veloxis Increases Share Capital in Connection with Exercise of Warrants
September 12, 2017 00:00 ET
|
Veloxis Pharmaceuticals A/S
Company Announcement no. 18/2017
To: NASDAQ Copenhagen...
Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2017
August 16, 2017 11:13 ET
|
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2017
Highlights
Revenue reached tUSD 16,168 in the first half of 2017 representing an...
Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 30 June 2017
July 03, 2017 14:00 ET
|
Veloxis Pharmaceuticals A/S
Company Release no. 16/2017
To: NASDAQ Copenhagen A/S ...
Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program
June 21, 2017 17:00 ET
|
Veloxis Pharmaceuticals A/S
Company Release no. 15/2017
To: NASDAQ Copenhagen A/S ...
Veloxis Increases Share Capital in Connection with Exercise of Warrants
June 14, 2017 23:00 ET
|
Veloxis Pharmaceuticals A/S
Company Release no. 14/2017
To: NASDAQ Copenhagen...
Veloxis Pharmaceuticals A/S Announces Agreement with Chiesi Farmaceutici S.p.A. to Commercialize Envarsus XR in China
June 05, 2017 20:38 ET
|
Veloxis Pharmaceuticals A/S
Company Release no. 13/2017
To: NASDAQ Copenhagen A/S ...
Veloxis Pharmaceuticals A/S and Endo Ventures Limited Jointly Announce Agreement for Paladin Labs Inc. to Commercialize Envarsus XR® in Canada
June 05, 2017 02:55 ET
|
Veloxis Pharmaceuticals A/S
Investor News no. 04/2017
To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 05 June...
Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2017
May 16, 2017 11:21 ET
|
Veloxis Pharmaceuticals A/S
Highlights
It is now estimated that over 6,000 patients in the US and Europe are being treated with Envarsus XR.
In the US, prescription growth of Envarsus in the first quarter...
Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 30 April 2017
April 29, 2017 18:00 ET
|
Veloxis Pharmaceuticals A/S
Company Release no. 11/2017
To: NASDAQ Copenhagen...